Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 164,448,896
  • Shares Outstanding, K 2,129,064
  • Annual Sales, $ 46,385 M
  • Annual Income, $ 6,994 M
  • 60-Month Beta 0.49
  • Price/Sales 3.54
  • Price/Cash Flow 6.22
  • Price/Book 5.19
Trade BMY with:

Options Overview Details

View History
  • Implied Volatility 21.65% ( +0.73%)
  • Historical Volatility 16.76%
  • IV Percentile 52%
  • IV Rank 39.85%
  • IV High 30.37% on 12/02/21
  • IV Low 15.86% on 08/06/21
  • Put/Call Vol Ratio 0.66
  • Today's Volume 10,318
  • Volume Avg (30-Day) 15,506
  • Put/Call OI Ratio 0.91
  • Today's Open Interest 772,037
  • Open Int (30-Day) 868,330

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate 1.91
  • Number of Estimates 6
  • High Estimate 2.00
  • Low Estimate 1.81
  • Prior Year 1.93
  • Growth Rate Est. (year over year) -1.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
73.35 +5.30%
on 04/29/22
78.46 -1.56%
on 05/18/22
+1.19 (+1.56%)
since 04/25/22
3-Month
67.29 +14.79%
on 02/28/22
78.46 -1.56%
on 05/18/22
+8.44 (+12.27%)
since 02/25/22
52-Week
53.22 +45.13%
on 11/30/21
78.46 -1.56%
on 05/18/22
+10.48 (+15.70%)
since 05/25/21

Most Recent Stories

More News
Bristol Myers Squibb to Participate in Bernstein’s 38th Annual Strategic Decisions Conference

Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Bernstein’s 38 th Annual Strategic Decisions Conference in New York, New York on Thursday, June...

BMY : 77.24 (+0.14%)
Why Did Warren Buffett Just Sell 1 of His Best Stocks of 2022?

The legendary investor just might regret selling this big-pharma stock.

BRK.A : 462,890.00 (-0.15%)
BRK.B : 308.64 (-0.17%)
ORCL : 69.83 (+1.16%)
BRK-A : N/A (unch)
BRK-B : N/A (unch)
BMY : 77.24 (+0.14%)
3 Pharmaceutical Stocks That Look Like Huge Bargains

Increasing investments in R&D and rising expenditure on healthcare are expected to bolster the pharmaceutical sector's growth. Therefore, we think the stocks of fundamentally sound pharmaceutical companies...

BAYRY : 17.0700 (+0.06%)
BMY : 77.24 (+0.14%)
CPRX : 6.88 (+0.15%)
Pfizer (PFE) Reports More Positive Data From Etrasimod Study

Pfizer (PFE) states that data from the ELEVATE 12 and ELEVATE 52 studies will form the basis of the regulatory submissions on etrasimod expected later this year

BMY : 77.24 (+0.14%)
PFE : 53.71 (+0.56%)
ALKS : 28.85 (+1.76%)
SESN : 0.5045 (-3.17%)
Why Roche Needs to Invest in At-Home Diagnostics

Declining demand for COVID-19 screening tests calls for a new focus.

RHHBF : 383.2500 (-0.20%)
BMY : 77.24 (+0.14%)
Merck's (MRK) Keytruda Gets CHMP Nod for Expanded Melanoma Use

Merck's (MRK) anti-PD-1 therapy Keytruda nears potential approval as an adjuvant treatment for adolescent pediatric patients with stage IIB, IIC or III melanoma following complete resection.

BMY : 77.24 (+0.14%)
MRK : 93.75 (-0.94%)
ALKS : 28.85 (+1.76%)
SESN : 0.5045 (-3.17%)
Mirati (MRTX) Seeks EU Nod for Adagrasib to Treat Lung Cancer

Mirati (MRTX) seeks a nod for its lung cancer candidate adagrasib in the European Union. A regulatory filing in the United States is currently under the FDA review with decision pending this year-end.

BMY : 77.24 (+0.14%)
MRK : 93.75 (-0.94%)
AMGN : 253.01 (+0.44%)
MRTX : 58.02 (-1.33%)
Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of scientific research across cancers and blood disorders at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and...

BMY : 77.24 (+0.14%)
3 Stocks Up 25% to 65% That Are Still Smart Buys

These high-flying stocks could continue soaring.

COMP : 5.30 (+0.76%)
BMY : 77.24 (+0.14%)
MCK : 333.48 (+1.42%)
DVN : 71.94 (+2.20%)
Biotech Stock Roundup: BBIO Up on BMY Deal, GILD & CMRX Offer Updates

Regulatory updates and acquisition news from Bristol Myers' (BMY) and BridgeBio Pharma (BBIO) are a few key highlights from the biotech sector during the past week.

BMY : 77.24 (+0.14%)
GILD : 65.01 (+1.03%)
CMRX : 1.7900 (-1.10%)
BBIO : 6.63 (-1.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products. It offers products which includes hematology, oncology, cardiovascular and immunology. Bristol-Myers Squibb Company, formerly known as Bristol-Myers Company, is based in...

See More

Key Turning Points

3rd Resistance Point 79.06
2nd Resistance Point 78.47
1st Resistance Point 77.85
Last Price 77.24
1st Support Level 76.64
2nd Support Level 76.05
3rd Support Level 75.43

See More

52-Week High 78.46
Last Price 77.24
Fibonacci 61.8% 68.82
Fibonacci 50% 65.84
Fibonacci 38.2% 62.86
52-Week Low 53.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar